Condividi contenuti The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Aggiornato: 33 min 51 sec fa

CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical Trials

Mer, 12/03/2014 - 12:49
Company Continues to Expect Clinical Trial Timelines to Remain Materially Unchanged and Expeditiously Resolved LOS ANGELES, Dec. 3, 2014 -- (Healthcare Sales & Marketing Network) -- CytRx Corporation (CYTR), a biopharmaceutical research and development...
Biopharmaceuticals, Oncology
CytRx, aldoxorubicin, Kaposi's Sarcoma, glioblastoma multiforme

US Medical Innovations, LLC Announces New Distribution Agreement With CrossLink Surgical, LLC

Mar, 12/02/2014 - 13:15
TAKOMA PARK, Md., Dec. 2, 2014 -- (Healthcare Sales & Marketing Network) -- US Medical Innovations (USMI), a Takoma Park, M.D. based biomedical device sales and distribution company announced today it has expanded its sales network through a distribution ...
Devices, Surgery, Distribution
US Medical Innovations, CrossLink Surgical, Canady Hybrid, Plasma Scalpel

Audentes Therapeutics Raises $42.5 Million in Series B Financing

Mar, 12/02/2014 - 13:09
Deerfield, Sofinnova, and Venrock Join Existing Investors to Propel Leading Gene Therapy Company Through Significant Clinical and Corporate Development Milestones SAN FRANCISCO--(Healthcare Sales & Marketing Network)--Audentes Therapeutics, Inc., a biot...
Biopharmaceuticals, Venture Capital
Audentes Therapeutics, gene therapy

Study Shows Prolaris(R) Could Save Healthcare System $6 Billion Over 10 Years

Mar, 12/02/2014 - 13:01
Additional Clinical Study Validates Active Surveillance Threshold Using Prolaris Score SALT LAKE CITY, Dec. 2, 2014 -- (Healthcare Sales & Marketing Network) -- Myriad Genetics, Inc. (MYGN) today announced that clinical data from three studies with Prol...
Diagnostics, Urology, Oncology
Myriad Genetics, Prolaris, prostate cancer

Xeltis Closes EURO 27 Million / USD 34 Million Series B Financing

Mar, 12/02/2014 - 12:53
ZURICH, Switzerland--(Healthcare Sales & Marketing Network)--Xeltis, a privately-held medical device company dedicated to transforming standards of care in heart valve replacement and vascular surgery, has announced that it has raised EURO 27 million (USD ...
Devices, Cardiology, Venture Capital
Xeltis , biodegradable heart valves, Endogenous Tissue Growth

Oncolytics Biotech(R) Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers

Mar, 12/02/2014 - 12:45
CALGARY, Dec. 2, 2014 -- (Healthcare Sales & Marketing Network) - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced that it has submitted applications for Orphan Drug Designation to the U.S. Food and Drug Administrati...
Biopharmaceuticals, Oncology
Oncolytics Biotech, REOLYSIN, pancreatic cancer, ovarian cancer

Avanir Pharmaceuticals To Be Acquired By Otsuka Pharmaceutical For $3.5 Billion

Mar, 12/02/2014 - 12:38
ALISO VIEJO, Calif., Dec. 2, 2014 -- (Healthcare Sales & Marketing Network) -- Avanir Pharmaceuticals, Inc. (AVNR) today announced that it has entered into a definitive agreement with Otsuka Pharmaceutical Co., Ltd. pursuant to which Otsuka will acquire A...
Biopharmaceuticals, Mergers & Acquisitions
Avanir Pharmaceuticals, Otsuka Pharmaceutical

New Hire Announcement - Vice President Of Sales And Business Development

Lun, 12/01/2014 - 13:10
ATLANTA, Dec. 1, 2014 -- (Healthcare Sales & Marketing Network) -- Dornier MedTech America is pleased to announce and welcome Jeff Howell as Vice President of Sales and Business Development. Jeff will be responsible for the leadership of the Dornier sale...
Devices, Urology, Personnel
Dornier MedTech, lithotripsy

Cepheid Receives FDA Clearance for Xpert Norovirus, the First On-Demand Molecular Test for Detection of Norovirus

Lun, 12/01/2014 - 13:06
Accurate Norovirus Detection in as Little as One Hour SUNNYVALE, Calif., Dec. 1, 2014 -- (Healthcare Sales & Marketing Network) -- Cepheid (NASDAQ: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) to market...
Diagnostics, FDA
Cepheid, Xpert Norovirus, norovirus

Ascendis Pharma A/S Completes $60 million Oversubscribed Series D Financing

Lun, 12/01/2014 - 13:00
Proceeds Will Be Used to Advance Clinical Programs in Growth Hormone Deficiency and Pulmonary Arterial Hypertension COPENHAGEN, Denmark, Dec. 1, 2014 -- (Healthcare Sales & Marketing Network) -- Ascendis Pharma A/S, a biotechnology company that applies...
Biopharmaceuticals, Venture Capital, Personnel
Ascendis Pharma, TransCon Growth Hormone, Growth Hormone

Lombard Medical Appoints William J. Kullback as Chief Financial Officer

Lun, 12/01/2014 - 12:55
Irvine, Calif. and LONDON, Dec. 1, 2014 -- (Healthcare Sales & Marketing Network) -- Lombard Medical, Inc. (EVAR), a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today announced the appointment...
Devices, Interventional, Personnel
Lombard Medical, abdominal aortic aneurysm

Cardio3 BioSciences Announces the Nomination of Three Co-principal Investigators for its CHART-2 Phase III Clinical Trial of C-Cure(R) for the Treatment of Heart Failure

Mer, 11/26/2014 - 14:14
Dr Bernard J. Gersh, Dr Thomas Povsic and Dr Gerasimos Filippatos will be Co-Principal Investigators of the phase III clinical trial CHART-2, authorized by the FDA in January CHART-2 is expected to start by the end of 2014 MONT-SAINT-GUIBERT, Belgium...
Regenerative Medicine, Cardiology
Cardio3 BioSciences, CHART-2 study, C-Cure, stem cell

Eleven Biotherapeutics Announces Additional Financing of $20 Million

Mar, 11/25/2014 - 15:37
Proceeds to Supplement Development of Potential Treatments of Moderate to Severe Dry Eye Disease, Moderate to Severe Allergic Conjunctivitis and Diabetic Macular Edema CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Eleven Biotherapeutics (EBI...
Biopharmaceuticals, Ophthalmology, Venture Capital
Eleven Biotherapeutics, Conjunctivitis, Diabetic Macular Edema

Vascular Solutions Receives 510(k) Clearance for Gel-Block(TM) 10x Embolization Product

Mar, 11/25/2014 - 15:34
Catheter-delivered gelatin pledgets targeting treatment of hypervascular tumors and arteriovenous malformations (AVMs) available for immediate U.S. launch Pre-formed, ready-to-deliver pledgets eliminate the need for physicians to cut and manufacture the...
Devices, Interventional, FDA
Vascular Solutions, Gel-Block, embolization, arteriovenous malformation

Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON(TM) Gel For The Treatment Of Acne Vulgaris

Mar, 11/25/2014 - 15:30
LAVAL, Quebec , Nov. 25, 2014 (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that it has received approval from the Food and Drug Administration (FDA) for ONEXTON™ Gel (clind...
Biopharmaceuticals, Dermatology, FDA
Valeant Pharmaceuticals, ONEXTON, clindamycin, acne vulgaris

Implanet Stands out at the North American Spine Society (NASS) Annual Meeting and Signs Six New Distribution Agreements

Lun, 11/24/2014 - 16:18
BORDEAUX, France & BOSTON--(Healthcare Sales & Marketing Network)--IMPLANET (IMPL.PA) (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, reports that its JAZZ implant was the ...
Devices, Orthopaedic, Neurosurgery, Distribution
Implanet, JAZZ implant, spine surgery

Bioniche Life Sciences Inc. Rebrands as Telesta Therapeutics Inc.

Lun, 11/24/2014 - 16:13
BELLEVILLE, ON , Nov. 24, 2014 (Healthcare Sales & Marketing Network) - Bioniche Life Sciences Inc. (TSX: BNC PNK: BNHLF) Bioniche Life Sciences today announced the accomplishment of another major milestone in the execution of its strategic plan to beco...
Biopharmaceuticals
Bioniche Life Sciences, Telesta Therapeutics

Agilis Biotherapeutics Names Former Shire Executive Dr. Gregory Robinson as Chief Scientific Officer

Lun, 11/24/2014 - 16:10
CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Agilis Biotherapeutics, LLC, a synthetic biology-based company focused on developing DNA-based therapeutics for rare genetic diseases, announced today that Greg Robinson, Ph.D., has been named Chief...
Biopharmaceuticals, Personnel
Agilis Biotherapeutics

Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices

Ven, 11/21/2014 - 13:34
DUBLIN, Ohio and MELVILLE, N.Y., Nov. 21, 2014 -- (Healthcare Sales & Marketing Network) -- Cardinal Health, Inc. (CAH), one of the world's largest health care services companies, and Henry Schein, Inc. (HSIC), the world's largest provider of health care ...
Biopharmaceuticals, Devices, Distribution
Henry Schein, Cardinal Health

Breckenridge Announces Appointment of New President

Gio, 11/20/2014 - 17:53
BOCA RATON, Fla., Nov. 20, 2014 -- (Healthcare Sales & Marketing Network) -- Breckenridge Pharmaceutical, Inc. announced the appointment of Larry Lapila to the position of President. Lapila previously served as Executive Vice President and has been with t...
Biopharmaceuticals, Personnel
Breckenridge Pharmaceutical

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong